CannEpil Global Licence Expands into Veterinary Healthcare
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Argent Biopharma Ltd has expanded its CannEpil® global licensing agreement to include veterinary healthcare applications, creating a new revenue stream alongside existing human therapeutic applications. The company will collaborate with Lupvindol UK Limited to navigate the U.S. FDA regulatory pathway for veterinary use. This strategic move aims to enhance long-term shareholder value by diversifying revenue sources and preserving ownership of CannEpil® intellectual property.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Argent Biopharma
- Quarterly Activities/Appendix 4C Cash Flow Report
- RGT Executes Global CannEpil Licensing Deal for US$5.5M
- Half Yearly Report and Accounts
- Provisional Patent Lodged with USPTO for NanoBodies Platform
- CannEpil - Largest Commercial Shipment Arrives in Ireland
Later from Argent Biopharma
- Notification of cessation of securities - RGT
- US Veterinary Development Programme for CannEpil Commences
- $250,000 in Funding Received under Financing Facility
- Proposed issue of securities - RGT
- FDA-CVM Establish INAD File for CannEpil Veterinary Program
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma